WO2005014654A3 - Product comprising a c4bp core protein and a monomeric antigen, and its use - Google Patents

Product comprising a c4bp core protein and a monomeric antigen, and its use Download PDF

Info

Publication number
WO2005014654A3
WO2005014654A3 PCT/IB2004/002717 IB2004002717W WO2005014654A3 WO 2005014654 A3 WO2005014654 A3 WO 2005014654A3 IB 2004002717 W IB2004002717 W IB 2004002717W WO 2005014654 A3 WO2005014654 A3 WO 2005014654A3
Authority
WO
WIPO (PCT)
Prior art keywords
core protein
product
c4bp core
monomeric antigen
monomeric
Prior art date
Application number
PCT/IB2004/002717
Other languages
French (fr)
Other versions
WO2005014654A2 (en
Inventor
Fergal Hill
Original Assignee
Avidis Sa
Fergal Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/008926 external-priority patent/WO2004016283A2/en
Application filed by Avidis Sa, Fergal Hill filed Critical Avidis Sa
Priority to US10/567,928 priority Critical patent/US20080311106A1/en
Priority to AU2004263387A priority patent/AU2004263387A1/en
Priority to JP2006523080A priority patent/JP2007528210A/en
Priority to CA002535517A priority patent/CA2535517A1/en
Priority to EP04769152A priority patent/EP1664124A2/en
Publication of WO2005014654A2 publication Critical patent/WO2005014654A2/en
Publication of WO2005014654A3 publication Critical patent/WO2005014654A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are useful as vaccines.
PCT/IB2004/002717 2002-08-14 2004-08-12 Product comprising a c4bp core protein and a monomeric antigen, and its use WO2005014654A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/567,928 US20080311106A1 (en) 2002-08-14 2004-08-12 Product Comprising a C4bp Core Protein and a monomeric Antigen, and Its Use
AU2004263387A AU2004263387A1 (en) 2003-08-12 2004-08-12 Product comprising a C4bp core protein and a monomeric antigen, and its use
JP2006523080A JP2007528210A (en) 2003-08-12 2004-08-12 Product comprising C4bp core protein and monomeric antigen and uses thereof
CA002535517A CA2535517A1 (en) 2003-08-12 2004-08-12 Product comprising a c4bp core protein and a monomeric antigen, and its use
EP04769152A EP1664124A2 (en) 2003-08-12 2004-08-12 Product comprising a c4bp core protein and a monomeric antigen, and its use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP03/08926 2003-08-12
PCT/EP2003/008926 WO2004016283A2 (en) 2002-08-14 2003-08-12 Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use

Publications (2)

Publication Number Publication Date
WO2005014654A2 WO2005014654A2 (en) 2005-02-17
WO2005014654A3 true WO2005014654A3 (en) 2005-10-13

Family

ID=34129903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002717 WO2005014654A2 (en) 2002-08-14 2004-08-12 Product comprising a c4bp core protein and a monomeric antigen, and its use

Country Status (5)

Country Link
JP (1) JP2007528210A (en)
CN (1) CN1867588A (en)
AU (1) AU2004263387A1 (en)
CA (1) CA2535517A1 (en)
WO (1) WO2005014654A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077976A2 (en) * 2004-02-13 2005-08-25 Avidis Sa Coiled-coil domains from c4b-binding protein
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
EP2397547A4 (en) 2009-02-10 2012-09-05 Univ Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
CN101838322A (en) * 2009-03-18 2010-09-22 中国医学科学院基础医学研究所 Malaria recombinant antigen, IgY immune body and malaria detection kit
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2851688B1 (en) * 2012-05-18 2019-06-05 Nitto Boseki Co., Ltd. Use of glycoprotein C4BPA as marker for detecting pancreatic cancer
KR102379951B1 (en) * 2013-03-18 2022-03-31 오시벡스 에스에이에스 Influenza nucleoprotein vaccines
DK3271729T3 (en) * 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv ANALYSIS OF RECOMBINANT EXPRESSION SYSTEMS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011461A1 (en) * 1990-01-26 1991-08-08 Biogen, Inc. C4 binding protein fusion proteins
US5219987A (en) * 1987-09-11 1993-06-15 Eniricerche S.P.A. Sequential polypeptides endowed with immunological activity
WO2004020639A2 (en) * 2002-08-14 2004-03-11 Avidis Sa Production of multimeric fusion proteins using a c4bp scaffold

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3037554B2 (en) * 1993-04-20 2000-04-24 寳酒造株式会社 Immunogenic artificial polypeptide
FR2744724B1 (en) * 1996-02-14 2002-08-02 Pasteur Institut RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PROTEIN MSP-1 OF A PLASMODIUM INFECTIOUS TO MAN FOR THE PRODUCTION OF ANTI-MALARIA VACCINES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219987A (en) * 1987-09-11 1993-06-15 Eniricerche S.P.A. Sequential polypeptides endowed with immunological activity
WO1991011461A1 (en) * 1990-01-26 1991-08-08 Biogen, Inc. C4 binding protein fusion proteins
WO2004020639A2 (en) * 2002-08-14 2004-03-11 Avidis Sa Production of multimeric fusion proteins using a c4bp scaffold

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. CHRISTIANSEN ET AL.: "Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.", JOURNAL OF VIROLOGY, vol. 74, no. 10, May 2000 (2000-05-01), USA, pages 4672 - 4678, XP002231126 *
E. SHINYA ET AL.: "In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads.", BIOMEDICINE AND PHARMACOTHERAPY, vol. 53, December 1999 (1999-12-01), Paris, France, pages 471 - 483, XP002231127 *
M. TONYE LIBYH ET AL.: "A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein.", BLOOD, vol. 90, no. 10, 15 November 1997 (1997-11-15), NEW YORK, NY, USA, pages 3978 - 3983, XP002231124 *

Also Published As

Publication number Publication date
CA2535517A1 (en) 2005-02-17
CN1867588A (en) 2006-11-22
WO2005014654A2 (en) 2005-02-17
JP2007528210A (en) 2007-10-11
AU2004263387A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2006061219A3 (en) Il-7 variants with reduced immunogenicity
WO2007062819A3 (en) Multimeric complexes of antigens and an adjuvant
MXPA03007319A (en) Modified anti-egfr antibodies with reduced immunogenicity.
DK1463751T3 (en) Albumin Fusion Proteins.
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
EP1615945A4 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2006082406A3 (en) Human antibodies and proteins
HK1195512A1 (en) Polysaccharide protein conjugate vaccines
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2004063963A3 (en) Novel proteins with altered immunogenicity
WO2005072223A3 (en) Engineered proteins, and methods of making and using
AU2002335613A1 (en) Biochips comprising nucleic acid/protein conjugates
HK1102306A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2008048945A3 (en) Conjugates of plasmodium falciparum surface proteins as malaria vaccines
WO2005014654A3 (en) Product comprising a c4bp core protein and a monomeric antigen, and its use
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2002098456A3 (en) Antigens and vectors for vaccination
AU2003290460A1 (en) Synthetic protein as tumor-specific vaccine
NL1024616A1 (en) Depot preparations in the form of a suspension.
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2003016551A3 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
WO2005065382A8 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029924.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006523080

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2535517

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004263387

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 547/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004769152

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004263387

Country of ref document: AU

Date of ref document: 20040812

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004263387

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004769152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10567928

Country of ref document: US